|Articles|January 18, 2022
Support for Title 21 CFR Part 11 and Annex 11 Compliance
Author(s)Agilent
This paper describes the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
Insuring Novel Biologic Development Against Geopolitical Developments: Part Three of Three with Abzena
3
Building Robust Biomanufacturing Networks for the Next Wave of Therapies
4
Accelerate Your Biologic with HEK Cell Lines
5